Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s):  MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines... see more

CSE:MDMA - Post Discussion

View:
Post by inviolablspirit on Nov 08, 2024 1:52pm

Financials

Just to caution people on financials, Pharmala's year end is in August so we will get the year end in December and that their Q1 3 month ends in November and those are released in January.   So I suspect any impact of these contracts may not be seen until Q2 financials which ends in February and are released at the end of April, as the actual clinical trials for some clients have not started and therefore sales may not be there yet from the recently announced contracts.  However, Pharmala has been supplying to Australia, Canada and the UK and so there should still be continued growth...   which is what we want to see for a positive move forward.  

Some people seem overly hyped on the financials on some of these other forums and don't seem to understand the company's financial release dates and when the sales of these contracts will begin to show up.  There will be a delay, but as more and more contracts are signed those financials will continue to grow each quarter.  

As early investors we are in the early stages of the company's financial growth and by looking ahead will probably continue to have some opportunities to add to positions before the company is actually noticed by the larger institutions and our American friends.  One would think names like John Hopkins, Harvard, Mt. Sinai, Texas and Yale would resonate with the American investor community at some point.  Pharmala has done some good PR work recently up in Canada, but need to get down into the US to promote the company.
Comment by inviolablspirit on Nov 08, 2024 2:00pm
...when I mean promote the company, I mean to the investor community in the US.  Clearly they have done an incredibly good job at bringing in clients from the US, but based on what I see on the investor side so far in US trades, the volume could certainly increase.    
Comment by Chefboy69 on Nov 08, 2024 2:19pm
Not sure who you are posting this garbage NOISE for? but i dn't squat for me my late father had a saying Bullsh.  baffles BRAINS
Comment by Chefboy69 on Nov 08, 2024 2:20pm
and YOU POST a lot of HORSE DUNG! just stay on CEO.CA
Comment by Chefboy69 on Nov 11, 2024 9:59pm
WHAT A FA inviolablspirit - (11/8/2024 1:52:01 PM) Financials Just to caution people on financials, Pharmala's year end is in August so we will get the year end in December and that their Q1 3 month ends in November and those are released in January.   So I suspect any impact of these contracts may not be seen until Q2 financials which ends in February and are released at the ...more  
Comment by inviolablspirit on Nov 18, 2024 3:28pm
Pharmala's Year-End is August 31, 2024 On a venture exchange these are the filing dates: Year End Filing date is Dec 30, 2024 Q1 filing date is Jan. 29, 2025 Q2 filing date is April 29, 2025 Q3 filing date is July 30, 2025 Last year Pharmala filed their Y/E on December 22, 2023.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities